The estimated Net Worth of Robert Benjamin Stein is at least $3.72 Millón dollars as of 15 May 2023. Dr Stein owns over 13,972 units of MiMedx Inc stock worth over $1,967,201 and over the last 11 years he sold MDXG stock worth over $906,917. In addition, he makes $842,383 as Exec. VP of R&D at MiMedx Inc.
Dr has made over 12 trades of the MiMedx Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 13,972 units of MDXG stock worth $83,832 on 15 May 2023.
The largest trade he's ever made was selling 51,756 units of MiMedx Inc stock on 4 May 2023 worth over $276,377. On average, Dr trades about 8,126 units every 28 days since 2014. As of 15 May 2023 he still owns at least 317,803 units of MiMedx Inc stock.
You can see the complete history of Dr Stein stock trades at the bottom of the page.
Dr. Robert Benjamin Stein M.D., Ph.D. is the Exec. VP of R&D at MiMedx Inc.
As the Exec. VP of R&D of MiMedx Inc, the total compensation of Dr D at MiMedx Inc is $842,383. There are 3 executives at MiMedx Inc getting paid more, with Timothy Wright having the highest compensation of $5,069,350.
Dr D is 70, he's been the Exec. VP of R&D of MiMedx Inc since . There are 4 older and 18 younger executives at MiMedx Inc. The oldest executive at MiMedx Group, Inc is Neil Yeston, 77, who is the Independent Director.
Robert's mailing address filed with the SEC is 1775 WEST OAK COMMONS COURT, , MARIETTA, GA, 30062.
Over the last 15 years, insiders at MiMedx Inc have traded over $15,165,698 worth of MiMedx Inc stock and bought 1,553,718 units worth $4,191,559 . The most active insiders traders include Fund Management Ltd.Okumus ..., Steve Gorlin y Parker H Petit. On average, MiMedx Inc executives and independent directors trade stock every 48 days with the average trade being worth of $487,865. The most recent stock trade was executed by William Frank Iv Hulse on 13 March 2024, trading 20,381 units of MDXG stock currently worth $162,029.
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and burns; AmnioFix, a semi-permeable protective barrier membrane product for the treatment of wounds related to surgical procedures; EpiCord and AmnioCord that are dehydrated human umbilical cord allografts intended for homologous applications; and AmnioFill that consists of particles of connective tissue matrix derived from placental disc and placental membranes. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
MiMedx Inc executives and other stock owners filed with the SEC include: